181 related articles for article (PubMed ID: 26277915)
1. CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection.
Tang W; Wang X; Chen Y; Zhang J; Chen Y; Lin Z
Pathol Biol (Paris); 2015 Sep; 63(4-5):190-8. PubMed ID: 26277915
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
3. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
[TBL] [Abstract][Full Text] [Related]
4. Arg kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion of glioma cells.
Chen L; Zhu M; Yu S; Hai L; Zhang L; Zhang C; Zhao P; Zhou H; Wang S; Yang X
Exp Cell Res; 2020 Apr; 389(1):111893. PubMed ID: 32035133
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma.
Ma J; Lang B; Wang X; Wang L; Dong Y; Hu H
J Clin Neurosci; 2014 Nov; 21(11):1885-90. PubMed ID: 25001988
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases.
Yopp AC; Shia J; Butte JM; Allen PJ; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S339-46. PubMed ID: 21584832
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
[TBL] [Abstract][Full Text] [Related]
8. Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information.
Maderna E; Salmaggi A; Calatozzolo C; Limido L; Pollo B
Cancer Biol Ther; 2007 Jul; 6(7):1018-24. PubMed ID: 17611402
[TBL] [Abstract][Full Text] [Related]
9. CXCL12/CXCR4 promotes motility and proliferation of glioma cells.
do Carmo A; Patricio I; Cruz MT; Carvalheiro H; Oliveira CR; Lopes MC
Cancer Biol Ther; 2010 Jan; 9(1):56-65. PubMed ID: 19923906
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
11. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.
Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C
Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015
[TBL] [Abstract][Full Text] [Related]
12. The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner.
Birner P; Tchorbanov A; Natchev S; Tuettenberg J; Guentchev M
J Clin Pathol; 2015 Oct; 68(10):830-4. PubMed ID: 26109200
[TBL] [Abstract][Full Text] [Related]
13. CXCR4: A Potential Marker for Inflammatory Activity in Abdominal Aortic Aneurysm Wall.
Tanios F; Pelisek J; Lutz B; Reutersberg B; Matevossian E; Schwamborn K; Hösel V; Eckstein HH; Reeps C
Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):745-53. PubMed ID: 26346005
[TBL] [Abstract][Full Text] [Related]
14. Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer?
Ingold B; Simon E; Ungethüm U; Kuban RJ; Müller BM; Lupp A; Neumann U; Ebert MP; Denkert C; Weichert W; Schulz S; Röcken C
PLoS One; 2010 Apr; 5(4):e10087. PubMed ID: 20386750
[TBL] [Abstract][Full Text] [Related]
15. Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism.
Munson JM; Bellamkonda RV; Swartz MA
Cancer Res; 2013 Mar; 73(5):1536-46. PubMed ID: 23271726
[TBL] [Abstract][Full Text] [Related]
16. The role of the CXCR4 cell surface chemokine receptor in glioma biology.
Ehtesham M; Min E; Issar NM; Kasl RA; Khan IS; Thompson RC
J Neurooncol; 2013 Jun; 113(2):153-62. PubMed ID: 23494875
[TBL] [Abstract][Full Text] [Related]
17. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.
Wagner PL; Hyjek E; Vazquez MF; Meherally D; Liu YF; Chadwick PA; Rengifo T; Sica GL; Port JL; Lee PC; Paul S; Altorki NK; Saqi A
J Thorac Cardiovasc Surg; 2009 Mar; 137(3):615-21. PubMed ID: 19258077
[TBL] [Abstract][Full Text] [Related]
18. Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor.
Lee HJ; Lee K; Lee DG; Bae KH; Kim JS; Liang ZL; Huang SM; Suk Oh Y; Kim HY; Jo DY; Min JK; Kim JM; Lee HJ
Clin Cancer Res; 2012 Jun; 18(12):3270-80. PubMed ID: 22553346
[TBL] [Abstract][Full Text] [Related]
19. Expression of CXC-motif-chemokine 12 and the receptor C-X-C receptor 4 in glioma and theeffect on peritumoral brain edema.
Tang W; Chen Y; Wang X; Chen Y; Zhang J; Lin Z
Oncol Lett; 2018 Feb; 15(2):2501-2507. PubMed ID: 29434965
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.
Rave-Fränk M; Tehrany N; Kitz J; Leu M; Weber HE; Burfeind P; Schliephake H; Canis M; Beissbarth T; Reichardt HM; Wolff HA
Strahlenther Onkol; 2016 Jan; 192(1):47-54. PubMed ID: 26374452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
